RIBOSOME SCIENTIFIC LTD

RIBOSOME SCIENTIFIC LTD

Statement of Financial Position

As at 31 December 2025

	2025 £		2024 £
Fixed assets		347		695
Current assets	45,427		57,585
Creditors: amount falling due within one year	(2,171)		(2,274)
Net current assets/(liabilities)		43,256		55,311
Total assets less current liabilities		43,603		56,006
Accruals and deferred income		(146)		(139)
Net assets/(liabilities)		43,457		55,867


Capital and reserves		43,457		55,867

Notes to the Accounts

Statutory Information

Ribosome Scientific Ltd is a private limited company, limited by shares, domiciled in England and Wales, registration number 08320927, registration address 55 Woodland Court, Dyke Road Avenue, Hove, BN3 6DQ.

The presentation currency is £ sterling.

1.	Accounting Policies Basis of accounting The financial statements are prepared under the historical cost convention and in accordance with the FRS 105 Financial Reporting Standard for Micro Entities (effective January 2016).

2.	Average number of employees Average number of employees during the year was 1 (2024: 1).

3.	Director's Advances, Credits and Guarantees As at 31st December 2025 Ribosome Scientific Ltd owed the director £1,165 (2024 - £2,274).

Director's Responsibilities:

For the year ended 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Signed on behalf of the board of directors:

---------------------------------------------

Nadia Hashash
Director

Date approved: 23 September 2026